SigrunHallmeyerMD

Chair, Cancer Committee, Advocate Lutheran General Hospital. Member, Division of Hematology/Oncology, Lutheran General Hospital. Oncology Specialists at Oncology Specialists, S.C.

Join to view full profile

Dr. Hallmeyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hallmeyer's full profile

Already have an account?

Office
1700 Luther Ln
Fl 2
Park Ridge, IL 60068
Phone+1 847-268-8200

Fax+1 847-318-2905
Is this information wrong?

Education & Training

University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 2002 - 2005
UPMC Medical Education (Harrisburg)Residency, Internal Medicine, 1999 - 2002
Humboldt University of Berlin - Charite Faculty of MedicineClass of 1998

Certifications & Licensure

IL State Medical License 2000 - 2026
PA State Medical License 2000 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
Terminated
Phase 4
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
Completed
Phase 2
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2013 May 01
Terminated
Phase 4
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Start of enrollment: 2013 Sep 06
Completed
Phase 1
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Completed
Phase 3
Effectiveness of the Advocate Lutheran General Survivorship Center Programs Start of enrollment: 2016 Oct 01
Completed
COVID-19 IgG Formation in Physicians at ALGH and Their Household Members Start of enrollment: 2020 Aug 26
Completed
Join now to see all

Publications & Presentations

PubMed

Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.
Ilana M Braun, Kari Bohlke, Donald I Abrams, Holly Anderson, Lynda G Balneaves, Gil Bar-Sela, Daniel W Bowles, Peter R Chai, Anuja Damani, Arjun Gupta, Sigrun Hallmeye...> ;Journal of Clinical Oncology. 2024 Mar 13
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study.
John M Kirkwood, Lisa A Kottschade, Robert R McWilliams, Nikhil I Khushalani, Sekwon Jang, Sigrun Hallmeyer, David F McDermott, Hussein Tawbi, Min Che, Cho-Han Lee, Co...> ;Immunotherapy. 2024 Jan 1
Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing.
Sigrun Hallmeyer, Michael A Thompson, Veronica Fitzpatrick, Yunqi Liao, Michael P Mullane, Stephen C Medlin, Kenneth Copeland, James L Weese> ;Biology Methods & Protocols. 2023 Jan 1
5 citations
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study.
Brendan D Curti, Jon Richards, John R Hyngstrom, Gregory A Daniels, Mark Faries, Lynn Feun, Kim A Margolin, Sigrun Hallmeyer, Mark Grose, Yiwei Zhang, Anlong Li, Rober...> ;Journal for Immunotherapy of Cancer. 2022 Dec 1
27 citations
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
Andrea Eisen, Mark R Somerfield, Melissa K Accordino, Phillip S Blanchette, Mark J Clemons, Sukhbinder Dhesy-Thind, Melissa S Dillmon, Stella D'Oronzo, Glenn G Fletche...> ;Journal of Clinical Oncology. 2022 Mar 1
1 citations
A Prospective, Longitudinal Evaluation of SARS-CoV-2 COVID-19 Exposure, Use of Protective Equipment and Social Distancing in a Group of Community Physicians.
Eli D Ehrenpreis, Sigrun Hallmeyer, David H Kruchko, Alexea A Resner, Nhan Dang, Natasha Shah, Nancy Mayer, Anne Rivelli> ;Healthcare. 2022 Feb 1
6 citations
Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies.
Michael A Thompson, Sigrun Hallmeyer, Veronica E Fitzpatrick, Yunqi Liao, Michael P Mullane, Stephen C Medlin, Kenneth Copeland, James L Weese> ;Journal of Patient-Centered Research and Reviews. 2022 Jan 1
2 citations
An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma
Merve Hasanov, Denái R. Milton, William H. Sharfman, Bret Taback, Lee D. Cranmer, Gregory A. Daniels, Lawrence E. Flaherty, Sigrun Hallmeyer, Mohammed M. Milhem, Lynn ...> ;Oncoimmunology. 2021 Oct 9
31 citations
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
Robert H.I. Andtbacka, Brendan D. Curti, Gregory A. Daniels, Sigrun Hallmeyer, Eric D. Whitman, Jose Lutzky, Lynn E. Spitler, Karl Zhou, Praveen K. Bommareddy, Mark Gr...> ;Journal of Clinical Oncology. 2021 Aug 31
73 citations
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Daniel J Olson, Zeynep Eroglu, Bruce Brockstein, Andrew Poklepovic, Madhuri Bajaj, Sunil Babu, Sigrun Hallmeyer, Mario R. Velasco, Jose Lutzky, Emily F. Higgs, Riyue B...> ;Journal of Clinical Oncology. 2021 May 4
181 citations
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomi...
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, M...> ;The Lancet. Oncology. 2021 May 1
32 citations
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomise...
Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Mesh...> ;The Lancet. Oncology. 2021 May 1
139 citations
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michele Maio, Karl D. Lewis, Lev V. Demidov, Mario Mandalà, Igor Bondarenko, Paolo A. Ascierto, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Gum...> ;The Lancet. Oncology. 2018 Apr 1
158 citations
Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Gui...
Jeanne Carter, Christina Lacchetti, Barbara L. Andersen, Debra L. Barton, Sage Bolte, Shari Damast, Michael A. Diefenbach, Katherine DuHamel, Judith Florendo, Patricia...> ;Journal of Clinical Oncology. 2017 Dec 11
25 citations
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinom...
Joseph I. Clark, Michael K.K. Wong, Howard L. Kaufman, Gregory A. Daniels, Michael A. Morse, David F. McDermott, Sanjiv S. Agarwala, Lionel D. Lewis, John H. Stewart, ...> ;Clinical Genitourinary Cancer. 2017 Feb 1
16 citations
Management of Breast Cancer during Pregnancy: Are We Compliant with Current Guidelines?
Victoria Shlensky, Sigrun Hallmeyer, Lourdes Juarez, Barbara V. Parilla> ;AJP Reports. 2017 Jan 1
15 citations
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E
Sigrun Hallmeyer, Rene Gonzalez, David H. Lawson, Lee D. Cranmer, Gerald P. Linette, Igor Puzanov, Bret Taback, C. Lance Cowey, Antoni Ribas, Gregory A. Daniels, Timot...> ;Melanoma Research. 2017 Dec 1
42 citations
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treat...
CM Robert H. I. Andtbacka Md, Sanjiv S. Agarwala, David W. Ollila, Sigrun Hallmeyer, Mohammed M. Milhem, Thomas Amatruda, John Nemunaitis, Kevin J. Harrington, Lisa Ch...> ;Head & Neck. 2016 Jul 13
30 citations
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Elizabeth I. Buchbinder, Anasuya Gunturi, Jessica C. Perritt, Janice P. Dutcher, Sandra Aung, Howard L. Kaufman, Marc S. Ernstoff, Girald P. Miletello, Brendan D. Curt...> ;Journal for Immunotherapy of Cancer. 2016 Sep 20
6 citations
Sequencing of New and Old Therapies for Metastatic Melanoma
Megan Ratterman, Sigrun Hallmeyer, Jon M. Richards> ;Current Treatment Options in Oncology. 2016 Aug 11
11 citations
Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
Mark R. Middleton, Stéphane Dalle, Joel Claveau, Pilar Mut, Sigrun Hallmeyer, Patrice Plantin, Martin Highley, Srividya Kotapati, Trong Kim Le, Jane Brokaw, Amy P. Abe...> ;Cancer Medicine. 2016 Apr 26
14 citations
High-Dose Radiation as a Dramatic, Immunological Primer in Locally Advanced Melanoma.
Majid Mohiuddin, Harold Park, Sigrun Hallmeyer, Jon M. Richards> ;Cureus. 2015 Dec 18
40 citations
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
Lawrence E. Flaherty, Omid Hamid, Gerald P. Linette, Lynn M. Schuchter, Sigrun Hallmeyer, Rene Gonzalez, C. Lance Cowey, Anna C. Pavlick, Fred J. Kudrik, Brendan D. Cu...> ;Cancer Journal. 2014 Jan 1
43 citations
Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide
Supriya Perambakam, Sigrun Hallmeyer, Samarth Reddy, Nadim Mahmud, Linda R. Bressler, Phillip J. DeChristopher, Delores Mahmud, Rafael Nunez, Jeffrey A. Sosman, David ...> ;Cancer Immunology, Immunotherapy. 2006 Sep 1
A randomized trial of PSA-peptide based, specific active immunotherapy in HLA-A2+ patients with prostate cancer: Comparison of two different vaccination strategies.
Hallmeyer S, Perambakam S, Reddy S, Mahmud N, Sosman J, David P> ;J. Clin. Oncol.. 2005-06-01
Join now to see all